Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Surrozen Shares Rally 25% in 7 Days Since Securing $95.1 Million Following FDA Milestone

Surrozen Secures $95.1 Million Following FDA Milestone for SZN-8141

+25.70% in 7 days $25.14 when we broke this story → $31.60 at 10:03 AM ET, 29 Oct 2026

Surrozen has completed the second and final tranche of a private placement, securing $95.1 million in gross proceeds. The funding was triggered by the FDA's clearance of the Investigational New Drug application for SZN-8141, a candidate for sight-threatening ophthalmic conditions. This capital injection significantly extends the company’s operational runway to support upcoming clinical trials.

Eye glasses, glasses, girl, shop. Stock photo illustrating Surrozen's capital raise story.
Surrozen, Inc./DE · Healthcare · Photo: newarta / Pixabay
Key numbers
Deal value$95M
Share of market cap32.2%

Key highlights

  • Gross proceeds of approximately $95.1 million from the second closing tranche
  • Funding triggered by achievement of milestone involving FDA clearance for SZN-8141
  • Expected cash runway now extends into 2029 for clinical operations
  • Issuance includes 5.7 million shares and warrants for another 6.5 million shares
  • Funds earmarked for DUET Phase 1b/2a study and SZN-8143 development

What Is the Capital Raise?

Surrozen finalized the second tranche of a private placement originally structured in March 2025, generating $95.1 million in gross proceeds before expenses. The closing involved the sale of 5,741,605 shares of common stock alongside pre-funded warrants for 2,456,500 shares at a purchase price of $11.60 and $11.5999 respectively. Additionally, investors received Series E common warrants to purchase approximately 4.1 million shares with an exercise price of $11.54. This financing event follows the achievement of a specific contractual milestone: the public announcement of FDA clearance for the company's Investigational New Drug application for SZN-8141 on October 2, 2026.

Use of Proceeds

  • Funding the DUET Phase 1b/2a study for lead ophthalmic candidate SZN-8141
  • Initiating clinical development and Phase 1b trials for the SZN-8143 program
  • Extending the company’s total cash runway through the 2029 fiscal year
  • Advancing the broader ophthalmology pipeline through multiple clinical milestones
  • Covering placement agent fees and general corporate operating expenses

Strategic Rationale

The capital raise positions Surrozen to maintain a disciplined approach to capital allocation while pursuing aggressive clinical timelines. By tying the final tranche to the FDA's IND clearance for SZN-8141, the company successfully de-risked the investment for institutional participants while ensuring immediate liquidity upon regulatory approval. This structured approach allows the company to transition from a discovery-stage entity to a mid-stage clinical developer. The resulting balance sheet strength is intended to support the company through the delivery of initial data for the DUET study, which is currently anticipated in the second half of 2027.

Business Overview

Surrozen is a biotechnology firm specializing in the development of targeted therapeutics that harness Wnt signaling pathways. These pathways are critical for tissue repair and regeneration, specifically within the eye to address drivers of sight-threatening diseases. The lead candidate, SZN-8141, is designed as an intravitreal injection for diabetic macular edema and neovascular age-related macular degeneration. It utilizes a dual-mechanism approach, combining Frizzled 4-mediated Wnt agonism with VEGF antagonism. Beyond its lead program, the company is developing SZN-8143, another targeted Wnt agonist, aimed at restoring vascular integrity in retinal diseases where current standard-of-care treatments may be insufficient.

Financial Context

  • Market capitalization stands at approximately $295.5 million following recent price action
  • Reported quarterly revenue of $5.0 million with annual revenue at $3.477 million
  • The company has approximately 17.8 million shares of common stock outstanding post-closing
  • Previous at-the-market offerings in 2025 and 2026 raised a combined $100 million
  • Current Relative Strength Index of 50.6 indicates neutral trading momentum
Surrozen, Inc./DE share price · last month
Line chart of Surrozen, Inc./DE's share price over the last month, from $23.84 on 19 Oct → $32.32 on 16 Nov; our story on 20 Oct at $25.14.

Up 28.6% since our story on 20 Oct: $25.14 when we broke it → $32.32 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$23.84
20 Oct$25.14
21 Oct$25.32
22 Oct$25.75
23 Oct$25.48
26 Oct$27.28
27 Oct$29.53
28 Oct$30.35
29 Oct$29.46
30 Oct$29.04
2 Nov$29.02
3 Nov$30.12
4 Nov$31.65
5 Nov$29.00
6 Nov$31.00
9 Nov$32.00
10 Nov$32.64
11 Nov$31.88
12 Nov$31.67
13 Nov$31.61
16 Nov$32.32
Earlier announcements by Surrozen, Inc./DE
DateAnnouncementAmount
30 Mar 2026At-the-market common stock offeringSource: stocktitan.net$50.0 Million
29 Aug 2025At-the-market common stock offeringSource: contracts.justia.com$50.0 Million
24 Mar 2025Two-tranche private placement of common stock and warrantsSource: surrozen.com$175.0 Million

Management commentary

“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”

Craig Parker, President and Chief Executive Officer

“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”

Craig Parker, President and Chief Executive Officer
Surrozen, Inc./DE · financial snapshot
Share price$25.14
Market cap$295M
Revenue (annual)$3M
1-month price change+51.90%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Surrozen, Inc. announcing the closing of the second tranche of its 2025 private placement.

Read the filing ↗
All Surrozen, Inc./DE filings and newsView all →

Track Surrozen, Inc./DE live

Get the next Surrozen, Inc./DE SEC filing seconds after it lands.

More from Surrozen, Inc./DE

All →

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.